{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:50:20Z","timestamp":1795031420783,"version":"4.10.2"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hematopoietic stem cell transplant\u2013associated thrombotic microangiopathy (TA-TMA) is a potentially fatal multisystem complication of hematopoietic cell transplantation for which there is no approved treatment. In a single-arm study (NCT02222545), narsoplimab treatment for TA-TMA demonstrated a median overall survival (OS) of 274 days from date of diagnosis. Here, we compare OS observed in 2 cohorts treated with narsoplimab to OS in a well-matched external control to test survival benefit in patients with high-risk TA-TMA. OS in patients (aged \u226516 years) with high-risk TA-TMA treated with narsoplimab in a single-arm, open-label study (NCT02222545) or in the narsoplimab expanded access program (EAP; NCT04247906) was compared with OS in a control group with high-risk TA-TMA from the Kyoto Stem Cell Transplantation Group (KSCTG) registry. Narsoplimab-treated patients in the single-arm study (N = 28) had a fourfold reduction in risk of mortality compared with patients from the KSCTG registry (N = 111; hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.19, 0.34; P &amp;lt; .0001). Similarly, in high-risk patients treated with narsoplimab in the EAP (N = 49), mortality risk was significantly lower than among high-risk patients from the KSCTG registry (N = 121; HR 0.38; 95% CI 0.28, 0.51; P &amp;lt; .0001). When narsoplimab-treated patients from the single-arm study and the EAP (N = 77) were compared with KSCTG patients, the HR for mortality was 0.28 (95% CI, 0.22, 0.37; P &amp;lt; .0001). In conclusion, in patients with high-risk TA-TMA, narsoplimab treatment significantly reduced mortality relative to a well-matched external control group who did not receive narsoplimab. These results support narsoplimab as a potential therapeutic option for TA-TMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017540","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:11:03Z","timestamp":1760123463000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7153-6713","authenticated-orcid":false,"given":"Hiroyuki","family":"Matsui","sequence":"first","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"2Department of Cytotherapy, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8959-6271","authenticated-orcid":false,"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"3Department of Hematology, Kobe City Hospital Organization, Kobe City Medical Center General Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle L.","family":"Schoettler","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Division of Hematology and Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Sorbonne University, Saint-Antoine Hospital, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale Unit\u00e9 Mixte de Recherche 938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"6Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"7Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-9815","authenticated-orcid":false,"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"9Department of Oncology and Hematology, University of Milan, Milan, Italy"},{"name":"10Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"3","key":"2026011309114269300_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"4","key":"2026011309114269300_bib2","first-page":"282.e1","article-title":"Systematic review of signs and symptoms associated with hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"29","author":"Dandoy","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026011309114269300_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.16621","article-title":"Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation","volume":"190","author":"Hildebrandt","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2026011309114269300_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/bmt.2017.207","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies","volume":"53","author":"Khosla","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"2026011309114269300_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JBM.S102235","article-title":"Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment","volume":"7","author":"Rosenthal","year":"2016","journal-title":"J Blood Med"},{"issue":"5","key":"2026011309114269300_bib6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ajh.27651","article-title":"Clinical outcomes and treatment strategies of adult transplant-associated thrombotic microangiopathy: external validation of harmonizing definitions and high-risk criteria","volume":"100","author":"Acosta-Medina","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"2026011309114269300_bib7","first-page":"102","article-title":"Novel use of ravulizumab in transplant-associated thrombotic microangiopathy: case report","volume":"13","author":"Gonzales","year":"2023","journal-title":"J Hematol Oncol Pharm"},{"issue":"2","key":"2026011309114269300_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","article-title":"Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study","volume":"58","author":"Svec","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2026011309114269300_bib9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026011309114269300_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.27186","article-title":"D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study","volume":"99","author":"Schoettler","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2026011309114269300_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41409-018-0256-8","article-title":"Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy","volume":"54","author":"Mart\u00ednez-Mu\u00f1oz","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026011309114269300_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2026011309114269300_bib14","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s12325-022-02184-4","article-title":"The role of complement in HSCT-TMA: basic science to clinical practice","volume":"39","author":"Meri","year":"2022","journal-title":"Adv Ther"},{"issue":"8","key":"2026011309114269300_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026011309114269300_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","article-title":"Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy","volume":"10","author":"Gavriilaki","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2026011309114269300_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41409-023-01951-3","article-title":"Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists","volume":"58","author":"Mahmoudjafari","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026011309114269300_bib18","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1371\/journal.pone.0000623","article-title":"Simultaneous activation of complement and coagulation by MBL-associated serine protease 2","volume":"2","author":"Krarup","year":"2007","journal-title":"PLoS One"},{"issue":"3","key":"2026011309114269300_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.13208","article-title":"The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation","volume":"14","author":"Kozarcanin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026011309114269300_bib20","author":"Demopulos","year":"26  2019"},{"issue":"1","key":"2026011309114269300_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/cei.13497","article-title":"MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab","volume":"203","author":"Elhadad","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"2026011309114269300_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cei\/uxad055","article-title":"MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence","volume":"213","author":"Elhadad","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2026011309114269300_bib23","author":"Galbusera","year":"2021"},{"issue":"22","key":"2026011309114269300_bib24","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026011309114269300_bib25","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.jtct.2024.01.045","article-title":"Real-world experience with narsoplimab (OMS721) for the treatment of transplant-associated thrombotic microangiopathy","volume":"30","author":"Adkins","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2026011309114269300_bib26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41409-024-02263-w","article-title":"Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus","volume":"59","author":"Alhomoud","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2026011309114269300_bib27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience","volume":"59","author":"Castelli","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026011309114269300_bib28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41409-025-02595-1","article-title":"Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)","volume":"60","author":"Chumnumsiriwath","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026011309114269300_bib29","author":"Romera","year":"2020"},{"issue":"11","key":"2026011309114269300_bib30","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/ajh.70044","article-title":"Narsoplimab results in excellent survival in adults and children with hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA)","volume":"100","author":"Schoettler","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"2026011309114269300_bib31","first-page":"336.e1","article-title":"Compassionate use narsoplimab for severe refractory transplantation-associated thrombotic microangiopathy in children","volume":"30","author":"Schoettler","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"suppl 4","key":"2026011309114269300_bib32","first-page":"S59","article-title":"A case of eculizumab-refractory transplant-associated thrombotic microangiopathy responsive to narsoplimab","volume":"83","author":"Tran","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2026011309114269300_bib33","first-page":"S309","article-title":"Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient","volume":"52","author":"Zecca","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2026011309114269300_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"13","key":"2026011309114269300_bib35","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2020002007","article-title":"Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT","volume":"4","author":"Matsui","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2026011309114269300_bib36","first-page":"151","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026011309114269300_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.2025028390","article-title":"High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study","volume":"146","author":"Vasu","year":"2025","journal-title":"Blood"},{"issue":"7","key":"2026011309114269300_bib38","first-page":"406.e401","article-title":"Impact of center experience with donor type on outcomes: a secondary analysis","volume":"28","author":"Brunstein","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"suppl 2","key":"2026011309114269300_bib39","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtct.2025.01.058","article-title":"Narsoplimab treatment for hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA) \u2013 real world outcomes from an expanded access program","volume":"31","author":"Schoettler","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"issue":"27","key":"2026011309114269300_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"2026011309114269300_bib41","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026011309114269300_bib42","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ajh.70022","article-title":"Eculizumab is associated with increased infection rates and infection related mortality in children with thrombotic microangiopathy after HCT","volume":"100","author":"Schoettler","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026011309114269300_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/hematology.2024000545","article-title":"Transplant-associated TMA: the conundrum of diagnosis and treatment","volume":"2024","author":"Li","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"2026011309114269300_bib44","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.bbmt.2018.12.840","article-title":"Thrombotic microangiopathy following pediatric autologous hematopoietic cell transplantation: a report of significant end-organ dysfunction in eculizumab-treated survivors","volume":"25","author":"Schoettler","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"2026011309114269300_bib45","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/111\/2478666\/blooda_adv-2025-017540-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/1\/111\/2478666\/blooda_adv-2025-017540-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:11:52Z","timestamp":1768313512000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/1\/111\/547663\/Survival-in-adults-with-high-risk-TA-TMA-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017540","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,13]]},"published":{"date-parts":[[2025,12,31]]}}}